Overall | N (%) | Â | N(%) |
---|---|---|---|
Age Quartile |  | Grade§ | Nmiss = 158 |
 Q1 [≤69] | 700 (26.2) |  Well differentiated | 712 (28.3) |
 Q2 [70–75] | 701 (26.2) |  Moderately differentiated | 1203 (47.8) |
 Q3 [76–80] | 609 (22.8) |  Poor/Undifferentiated | 602 (23.9) |
 Q4 [81+] | 665 (24.9) | Histology |  |
 Mean (Std) [IQR] | 74.8 (8.4) [11] |  Tube/colloid | 138 (5.2) |
Rural Status |  |  Other | 74 (2.8) |
 Metro | 1584 (59.2) |  Ductal/lobular | 2463 (92.1) |
 Urban | 967 (36.2) | Lymph Nodes |  |
 Rural | 124 (4.6) |  Positive | 413 (15.4) |
Singh Index |  |  Negative | 2262 (84.6) |
 Q1 [Highest SES] | 687 (25.7) | ER/PR positive | Nmiss = 99 |
 Q2 | 674 (25.2) |  Positive | 2264 (87.9) |
 Q3 | 649 (24.3) |  Negative | 312 (12.1) |
 Q4 [Lowest SES] | 665 (24.9) | Tumor Size | Nmiss = 88 |
 Mean (Std) [IQR] | 86.3 (13.3) [16] |  Q1 [≤ 9 mm] | 708 (27.4) |
Access to Near Radiation Facilities |  |  Q2 [10–13] | 601 (23.2) |
 Q1 [≤2] | 1056 (39.5) |  Q3 [14–20] | 727 (28.1) |
 Q2 [3–4] | 497 (18.6) |  Q4 [20+] | 551 (21.3) |
 Q3 [5] | 530 (19.8) |  Mean(Std)[IQR] | 15.7 (11.5) [11] |
 Q4 [6+] | 592 (22.1) | COC status |  |
 Mean (Std) [IQR] | 4.7 (4.7) [3] |  Yes | 1898 (71.0) |
Region |  |  No | 777 (29.1) |
 Kentucky | 251 (9.4) | SF Number of Beds | Nmiss = 32 |
 North Carolina | 504 (18.8) |  Mean (Std) [IQR] | 339 (244) [279] |
 Ohio | 525 (19.6) | SF Radiation Services | Nmiss = 45 |
 Pennsyvlania | 1395 (52.2) |  Yes | 2031 (77.2) |
Marital Status | Nmiss = 72 |  No | 599 (22.8) |
 Single | 1390 (53.4) | Optional RT | Nmiss = 176 |
 Married | 1213 (46.6) |  Yes | 1098 (43.9) |
Charlson Comorbidity Score |  |  No | 1401 (56.1) |
 0 | 1014 (37.9) | Surg Provider Volume | Nmiss = 134 |
 1 | 805 (30.1) |  Mean (Std) [IQR] | 16.2 (20.3) [20] |
 2+ | 856 (32.0) | Adjuvant Radiation Therapy |  |
 Meand (Std) [IQR] | 1.34 (1.62) [2] |  Yes | 2128 (79.6) |
Medicaid Dual |  |  No | 547 (20.5) |
 Yes | 387 (14.5) | OS Survival in months§§ |  |
 No | 2288 (85.5) |  Observed Mean | 5.5 (1.9) [2.0] |
Institutionalized | Â | Â | Â |
 Yes | 163 (6.1) |  |  |
 No | 2512 (94.9)) |  |  |
Stage | Â | Â | Â |
 Stage I | 1869 (69.9) |  |  |
 Stage II | 697 (26.1) |  |  |
 Stage III | 109 (4.1) |  |  |
First Cancer | Â | Â | Â |
 Yes | 2285 (85.4) |  |  |
 No | 390 (14.6) |  |  |